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Alberto Repossinia, Lorenzo Di Baccoa, Fabrizio Rosatia, Maurizio Tespilib,
Antonio Sainob, Alfonso Ielasib and Claudio MunerettoaAims Hybrid revascularization (HCR) has been recently
proposed as an alternative strategy in multivessel coronary
disease, particularly in patients with high SYNTAX scores and
risk scores. The objective of this study is to evaluate the
outcomes of HCR versus percutaneous coronary intervention
(PCI) drug-eluting stenting in left main treatment.
Methods A series of 198 consecutive patients with left main
stenosis have been treated. HCR, was performed in 77
patients (G1) whereas 121 patients (G2) received PCI on left
main. An adjusted analysis using inverse probability
weighting (IPW) was performed. Primary outcomes include:
30-day mortality, postoperative acute myocardial infarction,
18 months’ MACCEs: cardiac death, stroke, acute
myocardial infarction (AMI), repeated target vessel
revascularization (TVR).
Results SYNTAX score was 29.5W6.9 in G1 and 29.1W6.5
in G2 (PU0.529). In G2, three patients (2.7%) died because
of cardiogenic shock; no deaths occurred in G1 (PU0.603).
No major complications were reported in G1 and there was
no mortality at 18 months’ follow-up in both groups. Survival
freedom from MACCEs at 18 months’ follow-up was
significantly higher in G1 (G1: 93.3W4.6% versus G2:1558-2027  2018 Italian Federation of Cardiology. All rights reserved.
© 2018 Italian Federation of C72.3W6.3; PU0.001) mostly because of the higher freedom
from TVR (G1: 93.3W4.6% versus G2: 75.5W5.6; PU0.002).
At Cox regression analysis, PCI was an independent
predictor of MACCEs and TVR (hazard ratio 3.9, CI 1.36–9.6;
PU0.027).
Conclusion PCI in patients with left main and multivessel
disease is a viable strategy, with a good outcome. HCR,
demonstrated a lower incidence of cardiac adverse events
such as AMI and TVR. Future comparative studies will be
helpful to identify the optimal patient population for HCR.
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Percutaneous coronary intervention (PCI), thanks to the
improvement in results of the new generation of drug-
eluting stents (DES), is gaining more popularity in the
treatment of left main coronary lesions.1 Within the
SYNTAX trial, in the cohort of patients with left main
disease, similar results for the composite outcome were
reported for either patients undergoing coronary artery
bypass grafting (CABG) or percutaneous intervention.2
As left main lesions still represent a technical challenge
for PCI stenting, in particular, for complex or distal
lesions, US and European guidelines report that CABG
is still the gold standard therapy3,4 and that results after
PCI treatment are acceptable only for ostial/midshaft left
main or simple noncalcified lesions.5,6
Despite superiority of CABG on PCI for left main treat-
ment has been proven by several studies and randomized
trials7,8 in terms of reduced cardiac death, myocardial
infarction and particularly long-term freedom from
repeated coronary revascularization, in ‘real-world’ clin-
ical practice, the optimal strategy for coronary arteryrevascularization is still controversial, and PCI is largely
diffused for unprotected left main (ULM) treatment.
Nowadays hybrid coronary revascularization (HCR) strat-
egy is gaining new popularity in addition to CABG and
PCI for ULM treatment, combining the most proven
efficacious therapeutic proposals of cardiac surgery and
interventional cardiology, meaning minimally invasive
direct coronary artery bypass (MIDCAB) and PCI-stent-
ing for non-LAD lesions to perform a functionally
complete revascularization.
The current strategy offers to patients a solution inte-
grating all the advantages of both techniques, by avoiding
major surgical traumas, such as complete median stern-
otomy, aortic manipulation, use of cardiopulmonary by-
pass and cardioplegia and by reducing the rate of post-
operative complications of conventional CABG, such
as atrial fibrillation, bleeding, transfusions and lung
infections.9 On the other side, the combined technique
allows the rate of repeated TVR to be reduced, mainly
because of low-patency rate of complex left main
stent procedures.DOI:10.2459/JCM.0000000000000641
ardiology. All rights reserved.
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PCI outcomes in left main treatment have been
published1,10–13 whereas HCR versus CABG14 or
OPCAB9,15–17 experience in MVD patients is limited
and over a 10-year period cumulates approximately 500
patients from a number of small, single-center series.18–21
The only randomized trial to date is the Polish experi-
ence comparing hybrid approach to CABG/OPCAB
showing feasibility and safety of the hybrid approach
and reporting no differences in terms of graft patency
and stent restenosis at 12 months’ follow-up.22
HCR versus PCI studies demonstrated that the complex-
ity of the coronary lesion directly affects the outcomes of
PCI, especially the TVR, which is mainly concentrated in
the LAD, whereas PCI with DES for non-LAD offered
low and similar TVR rates in both HCR and PCI
groups.23
The only recently published multicenter observational
US study exploring outcomes of patients undergoing
HCR and multivessel PCI24 suggested that there is no
significant difference in MACCE rates.
We sought to investigate midterm outcomes in two
cohorts of patients with left main disease, treated by
HCR and multiple PCI.
Patients and methods
Study population
From January 2013 to June 2016, data were retrospect-
ively collected from 198 consecutive patients with left
main coronary disease treated, after heart team evalu-
ation, byHCR ormultivessel PCI with eitherDES or bare
metal stents (BMS). After multidisciplinary assessment
based on preoperative risk (Logistic EuroSCORE I) and
on coronary lesions complexity (SYNTAX score), 77
patients underwent HCR and 121 underwent multiple
PCI. The two groups were: HCR (LITA- LAD and PCI on other target vessels:
Group 1, G1) PCI (Group 2, G2).
Patients considered eligible to be scheduled in the study
were patients with critical left main stenosis or equivalent
left main lesion, with or without multivessel coronary
lesions.
Patients that underwent primary/rescue PCI for acute
coronary syndrome on non-LAD lesions with residual
lesions on left main were also considered in the study.
In particular, only patients with a coronary anatomy
suitable either for HCR and PCI were included in the
study: patients with distal heavy calcified lesions and
isolated ostial or proximal-mid-body left main disease
have been excluded from the study.© 2018 Italian Federation of CaOther exclusion criteria were patients undergoing con-
comitant surgical procedures in addition to myocardial
revascularization.
Primary endpoints include: 30-day mortality, postopera-
tive acute myocardial infarction (AMI) and survival free-
dom from MACCEs at 18 months: cardiac death, stroke,
AMI, repeated target vessel revascularization (TVR).
Secondary endpoints were survival freedom from TVR at
18 months’ follow-up and Cox regression analysis of
independent predictor factors for MACCE and TVR.
This study was approved by the Institutional Review
Board and no funding or industry support has to be
disclosed. All patients provided informed consent to be
enrolled in our institutional registry for patients with
coronary disease.
Statistical analysis
Continuous variables were reported as meanSD;
means were compared using Student’s t-test for independ-
ent samples. Categorical variables were expressed as
number of observations and percentage and they were
compared with Fisher’s exact test.
Inverse probability treatment weighting (IPTW) based
on propensity score evaluation was used in order to obtain
two balanced populations, reducing selection biases in
the two groups.
The propensity score was calculated for every patient
using a binary logistic regression, and 10 patients fromG1
and 13 patients from G2 were discarded because they
were outside the common support area after full-match
analysis. Variables used in the propensity analysis are
included in the analysis if P value was less than 0.10.
Then each patient was weighted by the inverse proba-
bility of receiving the treatment that they actually
received; the weight was calculated on the basis of
propensity score match value as following G1¼(1/
propensity score) and G2¼ [1/(1propensity score)].
Standardized difference in the weighted population for
covariates in the analysis was less than 10%.
Survival analysis was performed with weighted Kaplan–
Meier curves and population were compared by log-rank
test. A weighted Cox regression analysis was used to
verify if there were independent predictors for the hard
end points. It was verified by graphical method. Statistical
findings were considered significant if the critical level
was less than 5% (P< 0.05). Statistical analysis was per-
formed with SPSS software (Version 23, IBM, New York,
New York, USA).
Treatment strategy
HCR strategy and timing were chosen following a multi-
disciplinary discussion by the heart team: culprit lesion
was treated first and a sequential staged strategy was
utilized, with a timeframe of about 1–4 weeks betweenrdiology. All rights reserved.
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left main coronary disease, a surgical revascularization via
MIDCAB was performed as the first step of the hybrid
revascularization strategy, followed by PCI stenting
of circumflex artery and non-LAD lesions. No patient
in G1 had a simultaneous surgical and percutaneous
revascularization.
Surgical technique
In G1 patients, a standard MIDCAB was performed as
described elsewhere.25 A single lumen tube ventilation
was used in every case, the chest was opened through an
anterior left minithoracotomy in the fourth intercostal
space and LIMA was harvested as a skeletonized vessel
from the fourth to the first intercostal space with the
Thoralift retractor (US Surgical Corporation, Norwalk,
Connecticut, USA). Pericardium was incised horizontally
(parallel to the intercostal space) and LAD was explored.
If LAD was too lateral or the left lung was particularly
bulky, LIMA was harvested to the fifth intercostal space,
disarticulating the cartilage of the fifth rib, or to the sixth
rib by a fifth intercostal space approach. After systemic
heparinization (100 IU/kg) LIMA was interrupted dis-
tally and LAD was then occluded proximally using a
silicone vessel loop to avoid any direct compression on
the coronary wall. Distal occlusion was seldom necessary
and intracoronary shunts were never used. An 8-min
preconditioning was performed, without any hemo-
dynamic instability, major arrhythmias or significant
ST-T changes; LAD was incised after 1-min reperfusion.
The anastomosis was then performed with a single 8-0 or
7-0 polypropylene running suture. Local immobilization
of the myocardial surface was achieved using a pressure
stabilizer. At the end, the effect of heparin was reversed
with half dose of protamine.
Percutaneous coronary intervention
Coronary angiography was routinely performed via radial
artery. In 17 cases in HCR group and 14 cases in PCI
group, angiography was performed via femoral artery
because of severe atherosclerosis of radial and brachial
artery. Decision about PCI staging and stent selection
were left to the discretion of single operators: DES
(Cypher sirolimus, Cordis Johnson & Johnson, Warren,
New Jersey, USA; Taxus paclitaxel, Boston Scientific,
Natick, Massachusetts, USA and Xience everolimus,
Abbot Vascular, Santa Clara, California, USA) and
BMS were both used.
Antithrombotic therapy
In patients who underwent PCI beforeMIDCAB or those
who underwent MIDCAB before PCI but had a recent
acute coronary syndrome, and therefore were on double
antiplatelet therapy (Clopidogrel 75mg/day and Aspirin
100mg/day), only Clopidogrel was interrupted 3 days
before intervention. An early administration of Aspirin
was performed on the first postoperative day in addition© 2018 Italian Federation of Cto antithrombotic dose of low molecular weight heparin
(LMWH). Clopidogrel was administered on the second
postoperative day.
Follow-up
Follow-up visits were performed at 1 and 6 months
postoperatively and on a yearly basis thereafter; add-
itional clinical data were collected from referring cardiolo-
gists and general practitioners. Follow-up is 95.5%
complete (nine patients were lost at follow-up).
Results
Patient characteristics before matching
Before matching, 77 patients were in HCR group (G1)
and 121 patients in PCI group (G2). SYNTAX score was
29.3 7 in G1 and 27 6 in G2 (P¼ 0.151).
The mean age was significantly lower in G1 (66 10 in
G1 versus 70 9 years in G2; P¼ 0.019). EuroSCORE I
was 10.4 7.8 and 10.8 8.4 in G1 and G2, respectively,
P¼ 0.045. Patients in G1 had better mean left ventricular
ejection fraction (52 8 versus 49.5 7.1; P¼ 0.041) with
fewer women than in G2 (13 versus 30.6%; P¼ 0.006).
Dyslipidemia incidence was greater in G1 than in G2
(64.9 versus 57%, respectively; P¼ 0.049) whereas there
was only one REDO case in G1 (reintervention after
valvular cardiac surgery) versus 13 cases in G2 (1.3 versus
10.7%, respectively, P¼ 0.010). The number of patients
with CCS class greater than III was higher in G2 (26
versus 42.9%; P¼ 0.020). All the other preoperative vari-
ables were not statistically different in the two groups
(Table 1).
Patients characteristics after matching
After matching, there were 67 and 108 patients, respect-
ively, in G1 and G2 and no variables differed between
the two matched groups (Table 2). Preoperative char-
acteristics were balanced with the IPTWmethod derived
from the propensity score and after matching all stan-
dardized differences were less than 10% among variables.
SYNTAX score was 29.5 6.9 in G1 and 29.1 6.5 in G2
(P¼ 0.529) and EuroSCORE ILog was 12.9 14.6 versus
11.6 14.7, respectively, P¼ 0.329.
Intraoperative and early postoperative results
There were three emergency/urgency procedures in G1
and 23 in G2 (4.4 versus 21.3% respectively; P< 0.001).
Mean ICU stay for HCR patients was 17 4.5h andmean
mechanical assisted ventilation (MAV) was 7 2.1h; in
only one case, MAV was longer than 24h (1.4%).
In seven patients in G2 (6.4%), left main dissection
during the procedure occurred: two had fatal AMI and
cardiac arrest whereas five had an uneventful course.
One patient in G1 needed a reintervention for bleeding,
performed through the same left minithoracotomy
(1.4%), whereas in one case, postoperative bleedingardiology. All rights reserved.
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Table 1 Preoperative unmatched variables
Hybrid coronary revascularization (HCR), Percutaneous coronary intervention (PCI)
n, 77 (%) n, 121 (%) P value SD
Age (years) 6610 709 0.019 0.783
EuroSCORE I Log (meanSD) 10.47.8 10.88.4 0.045 0.031
Euro SCORE II (meanSD) 3.93.1 3.32.9 0.031 0.128
SYNTAX score 29.37.0 276 0.151 0.012
Ejection fraction (meanSD) 528.0 49.57.1 0.041 0.285
Female sex 10 (13) 37 (30.6) 0.006 0.380
Hypertension 56 (72.7) 73 (62.3) 0.092 0.252
Diabetes 20 (26) 41 (33.9) 0.271 0.166
CRF (GFR <30 ml/kg/min) 10 (13) 24 (19.8) 0.249 0.171
COPD 16 (20.8) 21 (17.4) 0.589 0.090
PAD 17 (22.1) 28 (23.1) 1.000 0.025
Previous CVA 14 (18.2) 14 (11.6) 0.214 0.206
Atrial fibrillation 4 (5.2) 16 (13.2) 0.090 0.236
Obesity (BMI >30) 16 (20.8) 19 (15.7) 0.445 0.139
Dyslipidemia 50 (64.9) 69 (57) 0.049 0.258
REDO 1 (1.3) 13 (10.7) 0.010 0.304
STEMI/nSTEMI less than 90 days 21 (27.3) 39 (32.2) 0.059 0.342
CCS class greater than III 20 (26.0) 52 (42.9) 0.020 0.252
CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accidents; NYHA, New York
Heart Association; PAD, peripheral artery disease; REDO, reoperation; SD, standardized differences; STEMI, ST elevation myocardial infarction.exceeded 1000ml anyhow not requiring surgical revision
(1.4%). One patient required conversion to sternotomy
and CPB because of intramural course of LAD (1.4%). In
five cases of HCR, all with left main equivalent lesions
with ostial stenosis of both LAD and circumflex artery
(Cx), PCI stenting from Cx to left main was performed
before MIDCAB. All the other patients in HCR group
received MIDCAB before PCI.
The mean number of diseased treated vessel was higher
in G2 (2.3 0.8 in G1 versus 2.7 0.7 in G2, P¼ 0.074).
There was no in-hospital mortality in G1 whereas three
patients died because of cardiogenic shock after PCI inG2
(G1: 0% versus G2: 2.7%; P¼ 0.603). No major postopera-
tive complications were reported in G1, whereas one
postoperative stroke and one myocardial infarctionTable 2 Preoperative matched variables
Hybrid coronary revascularization (HCR),
n, 67 (%)
Age (years) 689
EuroSCORE I Log (meanSD) 12.914.6
Euro SCORE II (meanSD) 3.42.9
SYNTAX score 29.56.9
Ejection fraction (meanSD) 51.810.2
Female sex 22.7
Hypertension 66.4
Diabetes 26.8
CRF (GFR<30 ml/kg/min) 16.5
COPD 19.3
PAD 19.9
CVA 15.3
Atrial fibrillation 6.8
Obesity (BMI >30) 15.3
Dyslipidemia 48.9
REDO 4.5
STEMI/nSTEMI less than 90 days 28.2
CCS class greater than III 35.8
CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary diseas
Heart Association; PAD, peripheral artery disease; REDO, reoperation; SD, standardi
© 2018 Italian Federation of Caoccurred in G2. Eleven patients in G1 required more than
two transfusions with packed red blood cells versus
four patients in G2 (16.2 versus 3.7%, respectively;
P¼ 0.027). One patient of each group required prolonged
catecholamines support (1.4% in G1 and 0.9% in G2,
P¼ 0.919) and only onepatient inPCI groupneeded IABP
positioning (0% in G1 versus 1.4% in G2; P¼ 0.839).
Postoperative atrial fibrillation incidence was significantly
higher in G1 than in G2 (11.9 versus 0.9%, respectively;
P¼ 0.008) whereas acute renal failure incidence was
significantly higher in G2 (0 versus 9.2%, respectively;
P¼ 0.003). Three cases of pneumothorax (4.4%) and six
cases of pleural effusion (8.9%) were reported in G1.
Pericardial effusion incidence was similar between the
two groups (4.4% in G1 versus 4.6 in G2; P¼ 0.984) never
requiring a revision. Results are reported in Table 3.Percutaneous coronary intervention (PCI),
n, 108 (%) P value SD
6911 0.278 0.112
11.614.7 0.329 0.105
3.43.2 0.087 0.014
29.16.5 0.529 0.065
50.710.7 0.309 0.105
24.8 0.717 0.061
64.7 0.745 0.044
30.8 0.426 0.111
17.9 0.785 0.055
19.9 0.897 0.020
23.4 0.454 0.133
12.9 0.555 0.105
10.0 0.355 0.227
16.4 0.888 0.045
47.8 0.837 0.085
5.7 0.846 0.020
29.5 0.472 0.091
38.9 0.625 0.050
e; CRF, chronic renal failure; CVA, cerebrovascular accidents; NYHA, New York
zed differences; STEMI, ST elevation myocardial infarction.
rdiology. All rights reserved.
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Table 3 In-hospital and 30-day outcomes
Hybrid coronary revascularization (HCR) Percutaneous coronary intervention (PCI),
n, 67 (%) n , 108 (%) P value
Emergency 3 (4.4) 23 (21.3) <0.001
ICU stay (meanSD; h) 174.5
MAV (meanSD; h) 72.1
PCI then MIDCAB 18
MAV greater than 24 h 1 (1.4)
In-hospital mortality 0 3 (2.7) 0.603
Stroke 0 1 (0.9) 0.839
Rethoracotomy for bleeding
Sternotomy 0
Lateral minithoracotomy 1 (1.4)
Bleeding greater than 1000 ml without reoperation 1 (1.4)
Transfusions greater than two PBRC 11 (16.2) 4 (3.7) 0.027
Low-cardiac output
Prolonged catecholamines 1 (1.4) 1 (0.9) 0.919
IABP necessary 0 1 (0.9) 0.839
Myocardial infarction 0 1 (0.9) 0.839
Reoperation for pericardial effusion 0
Postoperative atrial fibrillation 8 (11.9) 1 (0.9) 0.008
Pneumothorax 3 (4.4)
Pleural effusion 6 (8.9)
Pericardial effusion 3 (4.4) 5 (4.6) 0.984
Revision for pericardial effusion 0 0 1
Acute renal failure 0 10 (9.2) 0.003
Conversion to sternotomy 1 (1.4)
IABP, intra-aortic balloon pump; MAV, mechanical assisted ventilation; MIDCAB, minimally invasive direct coronary artery bypass; PBRC, packed red blood cells; PCI,
percutaneous coronary intervention.
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Mean follow-up was G1: 15.4 2.6 months versus G2
15.2 2.8 months; G1 1190 years/patients versus G2
1850 patient/years. No mortality at 18 months’ follow-
up was reported in both groups. Two major cerebral
adverse events and seven AMIs (in six cases receiving
TVR) were reported in G2 whereas neither strokes
nor myocardial infarction were registered in G1 at
follow-up. At 100% complete angiographic follow-up at
12 months, four cases of TVR were reported in G1: two
in-stent restenosis of left main-Cx stent, one case of
poststent stenosis and one in-stent restenosis on a right
coronary artery (RCA) lesion; no procedures on LAD for
LIMA-LAD graft failure or stenotic anastomosis were
reported. In G2, seven patients received plain old balloon
angioplasty (POBA; kissing balloon) on left main for
bifurcation initial restenosis; moreover, there were three
in-stent restenoses treated by new PCI, four cases of
poststent stenosis, two cases of incomplete distal stent
expansion and eight cases of in-stent restenosis on a
RCA lesion.
Survival freedom from MACCEs at 12 and 18 months’
follow-up (Fig. 1) was significantly higher in G1 (12
months, G1: 97.2 2.5% versus G2: 86.3 3.2; 18 months,
G1: 93.3 4.6% versus G2: 72.3 6.3; P¼ 0.001) mostly
because of the higher survival freedom from TVR (Fig. 2;
G1: 93.3 4.6% versus G2: 75.5 5.6; P¼ 0.002).
At Cox regression analysis, PCI stenting on left main was
an independent predictor ofMACCEs (hazard ratio 4.1, CI
2.4–11.3; P¼ 0.001) and TVR (hazard ratio 3.9, CI 1.36–
9.64;P¼ 0.002). Female sexwas an independent predictor
of TVR (hazard ratio 2.1, CI 1.12–4.65; P¼ 0.049).© 2018 Italian Federation of Cardiology. All rights reserved.
258 Journal of Cardiovascular Medicine 2018, Vol 19 No 5
Fig. 2
0.6
0.7
0.5
0.8
0.9
1.0
E
ve
nt
 f
re
e 
su
rv
iv
al
P = 0.002
0 3 6 12 15 189
Follow-up (months)
Patients at risk
PCI
HCR
67 67 61 54 41 4043
108 102 97 90 81 64 57
PCI
HCR
Groups
Survival freedom from target vessel revascularization. TVR, target vessel
revascularization.Discussion
CABG still remains the gold standard for the treatment of
significant left main stenosis. Nevertheless, PCI has
emerged as an alternative therapy for selected patients
with left main disease and in latest guidelines; it has
recently been upgraded to Class I for SYNTAX score 22
or less and to Class IIa for SYNTAX score between 23 and
32. Surgery is still mandatory whenever SYNTAX score is
at least 32.26
Although HCR has been considered in the past only
suitable for high-risk patients, it has recently gained a
new interest27,28 and nowadays HCR is considered as a
valid alternative to traditional surgical and interventional
strategies, mostly because of the proven long-term dur-
ation of left internal mammary artery (LIMA-LAD)
graft29 and to the improvement of DES results.1,5
Several observational analyses have demonstrated that
HCR is a well tolerated, feasible and minimally invasive
alternative to on–off pump CABG for treatment of left
main9,16,30 with comparable in-hospital and midterm
results. With an effective revascularization of LAD, left
main-PCI is a much simpler and safer procedure than
unprotected left main stenting (ULMS). Placement of a
single left main DES into the circumflex, as frequently© 2018 Italian Federation of Caoccurs, has no consequences and would be expected to
result in lower restenosis and TVR rates compared with
more complex stent procedures.31
In this study, the largest on this topic, we investigated the
midterm outcomes of HCR strategy for left main disease,
compared with multiple DES PCI. Because of lack of
data on HCR in left main patients, we compared our
clinical outcomes with the main studies on HCR inMVD
patients23,24 and with CABG, as standard surgical
approach.11
Patients with isolated ostial or proximal-mid-body left
main disease, who would currently be considered a low-
risk score and in whom PCI with stenting effectively
provides complete revascularization, have been excluded
from our series, our main concern being the competitive
flow to the LIMA-LAD system. Proximal LAD stenosis
must be always present in our ideal hybrid left
main patient.
In our clinically driven series, incidence of urgent pro-
cedures has been significantly higher in PCI group, being
responsible for a certain bias and limitation. Neverthe-
less, in-hospital mortality, AMI and periprocedural com-
plications were very low and similar in the two groups,
although slightly, but not significantly superior in the PCI
group. In particular, we experienced no deaths in G1 and
three cardiac deaths in G2 (2.7%), which is similar to
recent data of Delta Registry and other papers on left
main PCI32,33 with 2.3% cardiac death incidence in PCI
group and 1.1% in CABG group.
MI incidence was absent in G1 and 0.9% in G2, signifi-
cantly inferior to the reported 3.7% of PCI group and
particularly to 22.5% of the CABG group.11
Stroke incidence was similar in G1 and G2 (0 and 0.9%,
respectively) in line with the literature and inferior to
reported data for CABG.11 In our experience, G1 had a
significantly higher incidence of blood transfusions (16.4
versus 3.7%, P¼ 0.027) and postoperative atrial fibril-
lation (11.9 versus 0.9%, P¼ 0.008) compared with G2,
whereas acute renal failure was significantly higher in G2
(9.2 versus 0%, P¼ 0.003).
Results of the hybrid strategy are particularly encourag-
ing if we consider that our mean EuroSCORE in the
HCR group (G1: 12.9 14.6%) is much higher than in
Delta Registry for CABG (5.2 2.6)11 and in the main
HCR studies (3.1 2.3).23
Moreover, our cohort, identified by EuroSCORE greater
than 5 and SYNTAX score less than 32 reflects the ideal
HCR population, characterized by superior 30-day com-
posite cardiac and cerebrovascular outcomes in respect of
CABG.34
Survival freedom fromMACCEs at 18 months’ follow-up,
differently from results of Puskas et al.24 that reportrdiology. All rights reserved.
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significantly higher in G1 (93.3 4.6%) versus G2
(72.3 6.3%, P¼ 0.001) mostly because of the higher
freedom fromTVR. In particular, they reported a superior
stroke incidence in the HCR group, which was absent in
our series and five cases of PCI to theLADorLIMA-LAD
anastomosis, maybe because of robotic LIMA harvest
(54%), totally endoscopic coronary artery bypass (21%)
and cardiopulmonary bypass (8%) responsible for worse
results than standard MIDCAB.35 In our series, (100%
complete angiographic follow-up at 12 months) no proce-
dures on LAD for LIMA-LAD graft failure have been
performed, suggesting that the benefits of LIMA-LAD
over PCI in terms of patency rates or disease progression
seems to be crucial and explains the better freedom from
MACCEs outcomes.
No simultaneous surgical and PCI procedures have been
performed in G1, whereas 85% of G2 patients underwent
revascularization in a single-staged procedure. Aware of
other positive series15,23 and obvious advantages as
immediate angiography of LIMA-LAD and PCI of
high-risk lesions with documented patent LIMA-LAD,
we believe that single-step revascularization possibly
enhances bleeding and thrombotic risks, and no patients
in our HCR series underwent this strategy. A sequential
staged strategy was utilized, with a timeframe of about
1–4 weeks between the surgical and transcatheter pro-
cedure, and even in case of very critical high-risk left
main stenosis, no patient had MI or ischemic complica-
tions in the postoperative and pre-PCI period.
Study limitations
This is an observational retrospective and a propensity-
score adjustment and matching was performed to reduce
the imbalance between the two groups, and biases in the
study. The study was clinically and anatomically driven
after heart team discussion. The majority of DES used in
this study were first generation DES, and thus our results
may not reflect outcomes for left main-PCI with the
currently used newer DES, even if this does not affect
comparative results between the two groups.
Most emergent/urgent and unstable cases have been
included in G2 for ethical and clinical reasons, thus
creating a potential bias on early outcomes, which did
not affect results. As we do not have complete data
regarding the reasons for repeat revascularization (clinical
versus angiographic driven), we cannot exclude an exces-
sive unnecessary prudential repeat revascularization rate
in case of initial restenosis. Longer follow-up would help
allow a better understanding of the relative benefits of
HCR, especially in regard to multiarterial surgical revas-
cularization.
Conclusion
In this large series of HCR and multivessel PCI for
patients with left main stenosis, we demonstrated© 2018 Italian Federation of Cfavourable outcomes. For patients with a medium–high
EuroSCORE and SYNTAX score less than 32, HCRmay
provide a promising alternative to conventional CABG
and multiple PCI with similar postoperative results.
Risk-adjusted MACCEs rates at 18 months’ follow-up
were significantly increased in the PCI group mostly
because of the higher freedom from TVR and the proven
long-term duration of left internal mammary artery
(LIMA-LAD) graft in the HCR group. This favourable
observational study, all limitations considered, provides
evidence to support further investigation in HCR and the
need for future comparative trials with PCI, not only in
multivessel, but even in left main stenosis disease.
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